HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Anna Azvolinsky

Articles

FDA Grants Crizotinib Priority Review in ROS1-Mutated Lung Cancer

December 16, 2015

The targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.

Cetuximab Plus RT Linked With High Toxicity in Head and Neck Cancer

December 10, 2015

The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.

Patient Tumor Cell Assays Guiding Personalized Therapy

December 04, 2015

Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.

Nivolumab Improves Kidney Cancer Survival

November 10, 2015

The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).

High-Dose Combination Therapy Improves Outcomes in CNS Lymphoma

August 25, 2015

A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.

Novel Therapy for Resistant EGFR-Mutated Lung Cancer

May 26, 2015

Patients with EGFR-positive, non-small cell lung cancer (NSCLC) typically respond well to EGFR-targeted therapy, but eventually these tumors become resistant, leaving patients few options other than palliative care.

Gene Variants May Predict Prostate Cancer Progression on ADT

March 11, 2015

Inherited variants in an androgen transporter gene may determine the time to progression (TTP) for men with prostate cancer receiving androgen deprivation therapy (ADT).

Sorafenib nor Sunitinib Effective As Adjuvant Kidney Cancer Therapy

February 24, 2015

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.